Speaker Profile
Ph.D., CEO, Taudia
Biography
Paul J. Hung, PhD, is a serial life science entrepreneur. Paul previously co-founded CellASIC, acquired by MilliporeSigma in 2012, and COMBiNATi, acquired by Thermo Fisher Scientific in 2021. Following the latter acquisition, he led Thermo Fisher’s global digital PCR business. He also serves as a Venture Partner at Endurance28, supporting emerging life science companies.
Paul earned his PhD in Electrical Engineering and Computer Sciences from the University of California, Berkeley. His work bridges microfluidics, molecular measurement, and commercialization to translate technologies into practical tools for researchers and better patient care.
Talk
SPLASH: Open PCR Ecosystems for Ultrasensitive Proteomics
SPLASH brings ultrasensitive protein quantitation to the well-established, open PCR ecosystem, spanning manual benchtop workflows, laboratory automation, and integrated sample-to-answer systems. This presentation explores how SPLASH advances neurodegenerative biomarker research across compatible PCR platforms, giving laboratories flexibility to choose instrumentation, adapt workflows, and scale testing as their research needs evolve.
Clinical Dx Showcase:
Taudia
Taudia is a precision proteomics company advancing ultrasensitive blood-based biomarker assays for neurodegenerative diseases, with an initial focus on Alzheimer's Disease. Taudia’s SPLASH platform combines protein detection with established PCR infrastructure workflows to make biomarker research more accessible, scalable, and precise.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2027 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
